July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Five-year visual acuity outcomes after treatment for neovascular age-related macular degeneration at a large tertiary ophthalmic hospital
Author Affiliations & Notes
  • Thushanthi Ramakrishnan
    Moorfields Eye Hospital, London, London, United Kingdom
  • Katrin Fasler
    Moorfields Eye Hospital, London, London, United Kingdom
  • Reena Chopra
    Moorfields Eye Hospital, London, London, United Kingdom
  • Karsten Ulrich Kortuem
    Moorfields Eye Hospital, London, London, United Kingdom
  • Nikolas Pontikos
    Moorfields Eye Hospital, London, London, United Kingdom
  • Siegfried K Wagner
    Moorfields Eye Hospital, London, London, United Kingdom
  • Laxmi Raja
    Moorfields Eye Hospital, London, London, United Kingdom
  • Hasaneen Al Janabi
    Moorfields Eye Hospital, London, London, United Kingdom
  • Farid Afshar
    Moorfields Eye Hospital, London, London, United Kingdom
  • GABRIELLA CLAIRE PRESTON
    Moorfields Eye Hospital, London, London, United Kingdom
  • Konstantinos Balaskas
    Moorfields Eye Hospital, London, London, United Kingdom
  • Praveen Patel
    Moorfields Eye Hospital, London, London, United Kingdom
  • Adnan Tufail
    Moorfields Eye Hospital, London, London, United Kingdom
  • Pearse Keane
    Moorfields Eye Hospital, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Thushanthi Ramakrishnan, None; Katrin Fasler, Alfred Vogt Stipendium (F), Schweizerischer Fonds zur Verhütung und Be- kämpfung der Blindheit (F) (F); Reena Chopra, None; Karsten Kortuem, Google Deepmind, big picture (C), Lecture fee Bayer, Travel support Allergan (F); Nikolas Pontikos, None; Siegfried Wagner, None; Laxmi Raja, None; Hasaneen Al Janabi, None; Farid Afshar, None; GABRIELLA PRESTON, Bayer (R), City, University of London (E); Konstantinos Balaskas, None; Praveen Patel, Bayer (C), Genetech Inc (C), Heidelberg Inc (F), Merk Inc (C), Novartis (C), Roche UK (C), SalutarisMD (R), Thrombogenics NV (C), Thrombogenics NV (F), Topcon Inc (F); Adnan Tufail, Allergan (C), Bayer (C), Genentech (C), Heidelberg Engineering (C), Novartis (C), Novartis (F), Roche (C); Pearse Keane, Allergan (R), bayer (R), Google (C), Haag-Streit (R), Heidelberg Engineering (R), novartis (R), Topcon (R), Zeiss (R)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1471. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thushanthi Ramakrishnan, Katrin Fasler, Reena Chopra, Karsten Ulrich Kortuem, Nikolas Pontikos, Siegfried K Wagner, Laxmi Raja, Hasaneen Al Janabi, Farid Afshar, GABRIELLA CLAIRE PRESTON, Konstantinos Balaskas, Praveen Patel, Adnan Tufail, Pearse Keane; Five-year visual acuity outcomes after treatment for neovascular age-related macular degeneration at a large tertiary ophthalmic hospital. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1471. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The introduction of anti-VEGF for neovascular AMD has been a pivotal change in therapy for macular disease. Randomized clinical trials have shown efficacy up to 2 years of treatment, but data about long-term outcomes and side effects are scarce. With many patients needing lifelong treatment and the trend to individualized treatments (treat and extend) with various agents (bevacizumab, ranibizumab, aflibercept) it is crucial to outweigh the benefits and possible risks of different treatment approaches

Methods : A retrospective cohort study of all patients undergoing intravitreal therapy for neovascular AMD with at least 5 years (± 2 months) of follow-up (2007 to 2017) was carried out through an automated batch data export from the Moorfields Electronic Medical Record system, OpenEyes. Visual acuity was recorded in ETDRS letters. Missing values were sought from the electronic record and manually added. Patients received either aflibercept or ranibizumab, depending on the protocol in effect on day of injection. Statistical analysis was carried out using SPSS version 23

Results : A total of 950 eyes from 722 patients (63.7% female) that completed the 5 year follow-up were included. Mean age (SD) at beginning of treatment was 77 (±8) years. Mean follow-up time for those eyes was 6.4 years (range 4.8-9.7). Sixty-seven eyes (7.1%) had ranibizumab only, and 883 eyes (92.9%) switched from ranibizumab to aflibercept during the data collection period. There were no patients receiving aflibercept only for the whole 5year-period. Baseline visual acuity was recorded in 97% and had a mean (SD) of 59 (±23) letters. Mean (SD) visual acuity at 5 years was 60.4 (±17) letters. Of the eyes included, 19.2% had an improvement of >= 15 letters at 5 years, and 62.7% of eyes maintained a visual acuity within 15 letters of the baseline. Over 5 years, 18.1% of eyes lost 15 or more letters. A mean (SD) of 26 (±10) injections were given over the course of 5 years (7 in the first year, 5 in the second and third year, and 9 from year 3 to 5).

Conclusions : Long-term outcomes over 5 years under anti-VEGF therapy are promising and mostly maintain visual acuity compared to baseline. Automated assessment of retinal optical coherence tomography would provide further insight into disease course. There might be features in this imaging modalities, which are predictors of response to therapy

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×